Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
48.06
-0.24 (-0.50%)
Nov 20, 2026, 2:08 PM EST - Market open
Travere Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $73.43. The average 1-year stock price forecast is 52.79% higher than the current stock price, while the lowest is $62 (+29.01%) and the highest is $86 (+78.94%).
Price Target: $73.43 (+52.79%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $68 | Buy | Maintains | $68 | +41.49% | Nov 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $90 → $86 | Buy | Maintains | $90 → $86 | +78.94% | Nov 6, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Maintains $78 → $67 | Buy | Maintains | $78 → $67 | +39.41% | Nov 5, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $89 → $78 | Buy | Reiterates | $89 → $78 | +62.30% | Nov 4, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $70 → $72 | Buy | Maintains | $70 → $72 | +49.81% | Nov 4, 2026 |
Financial Forecast
Revenue This Year
765.32M
from 490.73M
Increased by 55.96%
Revenue Next Year
1.14B
from 765.32M
Increased by 48.63%
EPS This Year
0.78
from 0.91
Decreased by -14.19%
EPS Next Year
5.42
from 0.78
Increased by 593.81%
EPS and Forward PE are based on non-GAAP adjusted numbers.